The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Improving multiple myeloma outcomes beyond deeper responses
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses how outcomes for patients with multiple myeloma can be improved beyond achieving deeper responses. He highlights the need to improve outcomes for frailer patients and those with functional high-risk or post-CAR-T relapse, while also addressing survivorship, treatment-related complications and quality of life alongside disease control. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
